As I write this week’s blog, I’m preparing for commencement addresses at two schools of pharmacy: Auburn University’s Harrison School of Pharmacy, and Howard University School of Pharmacy. Walking around college campuses this time of year reminds me of the hope of the future, and as I strolled around the Loveliest Village on the Plains it hit me that there is a stark contrast between this week and next month for these graduates.

For the first time, Indian Americans are serving concurrent terms as presidential officers at three of the leading U.S. pharmacy organizations. Anandi Law, BPharm, MS, PhD, FAPhA, is president-elect of the American Association of Colleges of Pharmacy (AACP); Nishaminy (Nish) Kasbekar, PharmD, BSPharm, FASHP, is president of the American Society of Health-System Pharmacists (ASHP); and Alex C. Varkey, PharmD, MS, FAPhA, is president of the American Pharmacists Association (APhA).

Does taking the GLP-1 receptor agonist semaglutide for blood glucose control also lower the risk of clinically important kidney and cardiovascular outcomes? In the FLOW clinical trial, researchers found that of the 3,533 patients diagnosed with both T2D and chronic kidney disease, those taking semaglutide had a 24% lower risk of a primary-outcome event in the intervention group compared with the controls.

University of Florida Health has been awarded a stipend by CDC to run a program that aims to connect patients with high BP to community pharmacists.